Dexcel Pharma Technologies Ltd., 10% Owner at Urovant Sciences Ltd. (UROV), bought 15,000 shares at $8.30 ($125K) on 2019-06-12, disclosed to the SEC on 2019-06-14.
Open-market purchase of $124k UROV by 10% Owner. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $8.30 | 7,500 | $62K | 50.0% |
| 2 | $8.30 | 7,500 | $62K | 50.0% |
| Total | $8.30 avg | 15,000 | $125K | 100% |
| Filing → |
| UROV | BUY | 2019-06-19 | $262K | — | Filing → |
| UROV | BUY | 2019-06-11 | $292K | — | Filing → |
| MYOV | BUY | 2019-06-06 | $40.0M | — | Filing → |